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Objective: This multi-center, randomized, double-blind, phase 3 trial was conducted to compare the safety and efficacy of 
contrast agents iohexol-380 and iohexol-350 for coronary CT angiography in healthy subjects.
Materials and Methods: Volunteers were randomized to receive 420 mgI/kg of either iohexol-350 or iohexol-380 using a 
flow rate of 4 mL/sec. All adverse events were recorded. Two blinded readers independently reviewed the CT images and 
conflicting results were resolved by a third reader. Luminal attenuations (ascending aorta, left main coronary artery, and 
left ventricle) in Hounsfield units (HUs) and image quality on a 4-point scale were calculated.
Results: A total of 225 subjects were given contrast media (115 with iohexol-380 and 110 with iohexol-350). There was no 
difference in number of adverse drug reactions between groups: 75 events in 56 (48.7%) of 115 subjects in the iohexol-380 
group vs. 74 events in 51 (46.4%) of 110 subjects in the iohexol-350 group (p = 0.690). No severe adverse drug reactions 
were recorded. Neither group showed an increase in serum creatinine. Significant differences in mean density between the 
groups was found in the ascending aorta: 375.8 ± 71.4 HU with iohexol-380 vs. 356.3 ± 61.5 HU with iohexol-350 (p = 
0.030). No significant differences in image quality scores between both groups were observed for all three anatomic 
evaluations (all, p > 0.05).
Conclusion: Iohexol-380 provides improved enhancement of the ascending aorta and similar attenuation of the coronary 
arteries without any increase in adverse drug reactions, as compared with iohexol-350 using an identical amount of total 
iodine.
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Subjects
Adult healthy volunteers (age, 20–65 years) weighing 50 
to 90 kg were eligible for the study. Eligibility screening 
assessments included medical history taking, physical 
examination, pregnancy test, 12-lead electrocardiography 
examination, and laboratory evaluation. In addition to the 
absence of any known diseases, further specific exclusion 
criteria were as follows: history of hypersensitivity 
to iodinated contrast agents; known or suspected 
hyperthyroidism, pheochromocytoma, bronchial asthma, 
diabetes, myasthenia gravis, acute pancreatitis, vascular 
sclerosis, multiple myeloma or pulmonary hypertension; 
renal dysfunction; liver dysfunction; pregnant or lactating 
female; cardiac arrhythmia; or severe congestive heart 
failure (New York Heart Classification IV).
Contrast Media Administration
After enrollment in the study, volunteers were randomly 
assigned to receive either iohexol-350 (Bonorex 350; 
Centrial Medical Service, Seoul, Korea; 350 mg iodine per 
mL) or iohexol-380 (Bonorex 380; Centrial Medical Service, 
Seoul, Korea; 380 mg iodine per mL). Randomization 
sequence was created by a biostatistician with no clinical 
involvement in the trial using SAS statistical software 
(SAS system for Windows, version 9.2; SAS Institute, Cary, 
NC, USA), and stratified by center with a 1:1 allocation 
in a fixed block size of 4. Center-stratified randomization 
could allow for an equal allocation number of subjects to 
either group at each institute and thus avoid the effect 
from the use of different machines. Each pharmacy bulk 
package and iohexol container was identical in physical 
appearance and labeled with a random number. The 
treatment codes were concealed from the investigators 
enrolling participants, nurses, technicians, subjects, the 
independent readers, sponsor and their representatives. The 
treatment codes were delivered to the assistant investigator 
in sequentially numbered, opaque, sealed, and stapled 
envelopes, containing the information on a random number 
and the kind of contrast media. He/she measured the 
subjects’ body weight and calculated the contrast volume 
to be administrated to each subject. These envelopes were 
kept in a locked cabinet, the sole responsibility of, and 
accessible to, the unblinded assistant investigator alone. 
The assistant investigator was instructed not to reveal the 
information on the subjects’ body weight and treatment 
codes. He/she notified a random number to a pharmacist to 
deliver the contrast media labeled with the same number, 
INTRODUCTION
Computed tomography (CT) plays an important role in 
cardiovascular imaging (1, 2). However, there are some 
limitations in obtaining diagnostic quality images in 
clinical practice. Sufficient vascular enhancement is a 
prerequisite for the accurate detection of coronary artery 
stenosis on coronary CT angiography (3-5). Achieving 
optimal coronary enhancement is particularly important for 
coronary CT angiography as coronary arteries are of small 
caliber, have a tortuous course, and diminution of blood 
flow is observed in the presence of stenosis or obstruction 
(6). Coronary artery attenuation is determined by the iodine 
administration rate (6-8); therefore, improved coronary 
enhancement can be achieved by either increasing the 
injection rate or by increasing the iodine concentration 
of contrast media. However, increased injection rate has 
the following limitations for clinical use of coronary CT 
angiography (3, 9): 1) the injection rate used in clinical 
practice is already high, 4 to 5 mL/s; 2) larger needles, 
larger veins, and more set up time for the intravenous 
line would be necessary; and 3) the potential risk of 
contrast extravasation would increase. On the other hand, 
increasing the iodine concentration would be more feasible 
and without the above mentioned limitations. However, 
despite the several iodinated contrast media currently 
available on the market, high iodine concentration contrast 
media are very limited with only iopamidol-370 mgI/mL, 
iopromide-370 mgI/mL, and iomeprol-400 mgI/mL available 
(3, 10). Currently, another new high iodine concentration, 
nonionic monomer, low osmolar contrast medium, 380 mgI/
mL of iohexol is on trial. This multi-center, double-blind, 
randomized, comparative, phase 3 study was conducted 
to assess the safety and efficacy of the contrast agent, 
iohexol-380, for coronary CT angiography in comparison 
with iohexol-350 in healthy subjects.
MATERIALS AND METHODS
Study Design
This study was a multicenter, randomized, double-blind, 
active-controlled, parallel-group comparison conducted 
for a clinical trial 3rd phase according to the Guidelines of 
Good Clinical Practice with individual Institutional Review 
Board approval. Fourteen sites in Korea participated in the 
trial. All subjects provided written informed consent prior 
to enrollment.
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and the calculated contrast volume to a technician who 
would administer contrast media to a subject.
Contrast media were administered through dual-head 
power injection into a peripheral vein of the right arm via 
an 18 G venous catheter. All volunteers in both groups were 
administered 420 mgI/kg of contrast media with the same 
flow rate of 4 mL/sec, followed by a 40-mL saline flush (0.9% 
NaCL solution). For example, a subject weighing 70 kg was 
given 77.4 mL of iohexol 380 mgI/mL (420 mgI/kg divided 
by 380 mgI/mL multiplied by 70 kg) and 84 mL of iohexol 
350 mgI/mL (420 mgI/kg divided by 350 mgI/mL multiplied 
by 70 kg). Therefore, the total iodine amount was identical 
in both groups. Since volunteers weighing 50 to 90 kg 
were enrolled in the trial, volunteers in the iohexol-380 
group were administered 55.3–99.5 mL of contrast medium 
with an iodine flux of 1.52 gI/s, corresponding to an 
injection duration of 14–25 seconds. The volunteers in the 
iohexol-350 group were administered 60–108 mL of contrast 
medium with an iodine flux of 1.4 gI/s, corresponding to 
an injection duration of 15–27 seconds.
MDCT Angiography Protocol
Subjects underwent coronary CT angiography with five 
different 64 or 128-channel multidetector CT (MDCT) 
scanners: a 64-channel dual-source CT scanner (SOMATOM 
Definition; Siemens Medical Solutions, Forchheim, Germany), 
a 128-channel dual-source CT scanner (SOMATOM Definition 
Flash; Siemens Medical Solutions), two 64-channel MDCT 
scanners (Brilliance 64, Philips Medical Systems, Best, the 
Netherlands; GE LightSpeed VCTXT, General Electric Medical 
Systems, Milwaukee, WI, USA), and a 128-channel MDCT 
scanner (SOMATOM Definition AS Plus; Siemens Medical 
Solutions). Each institute followed a standardized protocol 
for the CT examination: craniocaudal direction; retrospective 
gating; bolus tracking in the descending aorta with a 100 
Hounsfield units (HU) trigger and 8 second delay; tube 
voltage, 120 kVp; tube current-time product, adjustable; 
detector configuration, 64 x 0.6–0.625 mm, 32 x 0.6 or 64 x 
0.6 mm in scanners; table speed, 0.2 pitch; gantry rotation 
time, 0.28–0.42 msec; matrix, 512 x 512; reconstruction 
slice thickness, 1 mm; reconstruction interval, 0.5–1 mm; 
and a standard algorithm reconstruction. Prospective 
sequential scanning was not allowed.
Safety Assessment
Figure 1 demonstrated an overview of study flowchart 
(Supplementary Table 1 in the online-only Data 
Supplement). In brief, laboratory tests including hematology 
and biochemistry were twice taken at least 14 days before 
and 24 hours after the CT examination: serum creatinine 
was also included (Supplementary Table 1 in the online-only 
Data Supplement). All subjects were monitored thrice by 
the research nurse at each institute at the visit on the day 
of CT examination and 24 hours after CT examination and 
on the phone 7 days after the CT examination for adverse 
events including a description of the event and the severity. 
The severity of adverse events was graded as mild, moderate 
or severe; mild, usually transient in nature and generally 
not interfering with normal activities; moderate, sufficiently 
discomforting to interfere with normal activities; and 
severe, incapacitating and prevents normal activities.
Efficacy Assessment
All CT images were interpreted by an independent 
review board, which consisted of three board-certified 
cardiovascular radiologists. Two readers (3-year and 9-year 
experiences in cardiovascular imaging) independently 
reviewed the CT images quantitatively and qualitatively. 
Any conflicting results between the two readers were finally 
resolved by the third reader (10-years of experience in 
cardiovascular imaging). The third reader also reviewed all 
CT images for technical adequacy and decided if the image 
sets were to be excluded for the efficacy assessment in 
case of severe motion, inadequate scan range, insufficient 
radiation, or other factors. All readers were fully blinded 
to patients allocation, as well as all clinical and other 
radiologic information.
Quantitative Efficacy Assessment: Contrast Enhancement
Vessel densities (in HU) were independently measured 
             Fig. 1. Study flow.
1st visit:
screening
2nd visit: CT scan 3rd visit: safety 
laboratory tests
Telephone call: 
safety follow-up
Up to 14 days 
before CT scan
Randomization, double-blind 
allocation: iohexol-380
vs. iohexol-350 mgI/mL
24 hours after iohexol 
administration
7 days after CT scan
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by the two readers using circular regions of interest (ROIs) 
manually placed in the following regions: mid-portion of 
the ascending aorta for primary outcome measure, and mid-
portion of left main coronary artery and the apical cavity 
of the left ventricle for secondary outcome measures (Fig. 
2). ROIs were drawn as large as appropriate to avoid vessel 
Fig. 2. Assessment of attenuation in three anatomical regions including ascending aorta (A), left main coronary artery (B), and 
left ventricular cavity (C). Circles indicate regions of interest placed at each region.
A B C
             Fig. 3. Flow diagram of study patients.
Assessed for eligibility (n = 276)
Excluded (n = 48)
· Not meeting inclusion criteria (n = 36)
· Declined to participate (n = 12)
Randomized (n = 228)
CT performed (n = 114)
Analyzed for efficacy assessment (n = 114)
CT performed (n = 110)
Analyzed for efficacy assessment (n = 110)
Allocated to iohexol-380 group (n = 115)
· Received allocated iohexol-380 (n = 115)
Allocated to iohexol-350 group (n = 113)
· Received allocated iohexol-350 (n = 110)
· Did not receive allocated iohexol-350 due 
   to failure to meet inclusion criteria (n = 3)
   - Abnormal skin test (n = 2)
   - Blood pressure increase (n = 1)
Analyzed for safety assessment (n = 115) Analyzed for safety assessment (n = 110)
Excluded (n = 1)
· Declined to participate (n = 1)
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walls, atheroma, or trabeculae. In subjects in whom there 
were differences of < 5 HU between the two readers, the 
average of the two measurements was used. In any subjects 
with a difference of > 5 HU, the measurements from the 
third reader were considered as the final results.
Qualitative Efficacy Assessment: Image Quality Scoring
All evaluable coronary artery segments for three different 
anatomic regions including the ascending aorta, left main 
coronary artery, and the left ventricle were independently 
analyzed by two readers using the following 4-point scale: 
1 (nondiagnostic), impaired image quality with poor 
definition of objects owing to inadequate enhancement and 
excessive image noise; 2 (adequate), evident limitations 
in vessel or left ventricular wall definition and in contrast 
resolution with suboptimal enhancement and moderate 
image noise; 3 (good), minimal limitations in vessel or 
left ventricular wall definition and in contrast resolution 
with sufficient enhancement and mild image noise; and 
4 (excellent), excellent attenuation in the vessel lumen 
and clear vessel wall definition with barely perceived 
image noise (11). A decrease in image quality from motion 
and poor gating were not considered in the subjective 
assessment, as they are not likely to be affected by which 
contrast media was used (11). All conflicting results were 
reviewed and the final score was decided by the third 
reader.
Statistical Analysis
Sample size was calculated using an nQuery Advisor 
Table 1. Study Population Demographic Characteristics
Iohexol-380 (n = 114) Iohexol-350 (n = 110) P
Age (yr)* 36.8 ± 10.2 36.5 ± 10.5 0.799
Gender (male), n 70 (61.4%) 58 (52.7%) 0.189
Heart rate (beat per minute)*† 74.2 ± 11.5 72.2 ± 10.3 0.172
Systolic pressure (mm Hg)*† 117.8 ± 13.2 115.6 ± 13.5 0.218
Diastolic pressure (mm Hg)*† 73.7 ± 10.6 73.3 ± 10.4 0.776
Weight (kg)* 65.9 ± 10.3 66.1 ± 10.4 0.926
Height (cm)* 168.0 ± 8.7 167.6 ± 9.2 0.737
Body mass index (kg/m2)* 23.3 ± 2.7 23.5 ± 2.6 0.674
Any concomitant medication, n 63 (54.8%) 58 (52.7%) 0.788
Beta blocker medication, n 26 (22.6%) 26 (23.6%) 1.000
*Data are presented as mean ± standard deviations, †Indicates values obtained just before CT examinations.
Table 2. Adverse Drug Reactions
Iohexol-380 (n = 115) Iohexol-350 (n = 110)
P
n (%) Events n (%) Events
Any adverse drug reactions 56 (48.7) 76 51 (46.4) 74 0.690
General disorders and administration site conditions
Feeling hot 46 (40.0) 46 46 (41.8) 46 0.788
Facial edema 1 (0.9) 1 0 (0.0) 0 1.000
Nervous system disorders
Headache 10 (8.7) 10 14 (12.7) 14 0.390
Dizziness 5 (4.3) 5 3 (2.7) 3 0.722
Paraesthesia 0 (0.0) 0 1 (0.9) 1 0.488
Skin and subcutaneous tissue disorders
Urticaria 3 (2.6) 3 5 (4.5) 5 0.491
Pruritus 2 (1.7) 2 2 (1.8) 2 1.000
Cold sweat 1 (0.9) 1 0 (0.0) 0 1.000
Rash 1 (0.9) 1 0 (0.0) 0 1.000
Gastrointestinal disorders
Nausea 6 (5.2) 6 3 (2.7) 3 0.499
Respiratory disorders
Dyspnea 1 (0.9) 1 0 (0.0) 0 1.000
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program (nQuery Advisor, version 5.0, Statistical Solutions, 
Cork, Ireland) based on a t test to compare means between 
iohexol-380 and iohexol-350 groups. The minimum 
number of subjects required to have a power of 90% to 
discriminate between HU after the two regimens was 206 
(103 in each group) and the maximum was 228 assuming 
a 10% attrition rate. Mean and standard deviation of the 
difference used were 25 HU and 55 HU, respectively, as 
described in a previous comparative study on iodixanol-320 
and iohexol-350 by Tsai et al. (12). The Student t test for 
continuous variables and the χ2 test for categorical variable 
were used to compare the iohexol-380 and iohexol-350 
groups. Estimated effect size and 95% confidence intervals 
were provided for the comparison of primary and secondary 
measures between two groups. All statistical tests were 
performed at a significance level of p < 0.05 using a 
statistical software package (SAS system for Windows, 
version 9.2).
RESULTS
Study Population
Between July 20, 2012 and January 3, 2013, of the 276 
subjects enrolled in the study, 48 were excluded after the 
screening test and 228 (82.6%) were randomly allocated to 
one of two contrast agent groups (115 in the iohexol-380 
group and 113 in the iohexol-350 group) (Fig. 3). Among 
them, 4 subjects dropped out at the beginning of the study 
and 1 of them was administered contrast agents. Thus, 225 
(115 in iohexol-380 and 110 in iohexol-350) were evaluated 
for safety assessment and 224 (114 in iohexol-380 and 
110 in iohexol-350) for efficacy assessment. Demographic 
characteristics between the iohexol-380 and iohexol-350 
groups showed no significant differences (Table 1).
Safety Assessment
The volunteers in the iohexol-380 group were 
administered an average of 72.8 mL (standard deviation, 
11.3 mL; range, 55.8–97.6 mL) of contrast medium, 
corresponding to an injection duration of 14–24 seconds. 
The volunteers in the iohexol-350 group were administered 
an average of 79.3 mL (standard deviation, 12.5 mL; range, 
70.1–106.8 mL) of contrast medium, corresponding to an 
injection duration of 17–27 seconds.
Mean values of white blood cell count, total protein, 
and albumin were significantly decreased after contrast 
administration in the iohexol-350 group although their Ta
bl
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changes were minimal (all p < 0.05), but differences in 
changes between the two groups were not significant 
(all, p > 0.05) (Supplementary Tables 2, 3 in the online-
only Data Supplement). Mean values of eosinophil% and 
total bilirubin were significantly increased after contrast 
administration in both groups, without significant 
differences in changes between the two groups (all, p > 
0.05) (Supplementary Tables 2, 3 in the online-only Data 
Supplement). No increase in serum creatinine above normal 
limits was found in either group (Supplementary Table 3 in 
the online-only Data Supplement).
The total number of adverse drug reactions was 150 
events in 107 (47.6%) of 225 subjects: 76 events in 56 
(48.7%) of 115 subjects in the iohexol-380 group vs. 74 
events in 51 (46.4%) of 110 subjects in the iohexol-350 
group (p = 0.690) (Table 2). Neither moderate or severe 
adverse drug reactions were recorded. The major adverse 
drug reactions reported in the iohexol-380 group were 
feeling hot in 46 (40.0%) subjects, followed by headaches 
in 11 (9.6%) subjects, and nausea in 6 (5.2%) subjects. 
Similarly, the major adverse drug reactions in the 
iohexol-350 group were also feeling hot in 46 (41.8%) 
subjects, followed by headaches in 15 (13.6%) subjects and 
urticaria in 5 (4.5%) subjects. There were no differences in 
frequency according to the types of adverse drug reactions 
between the iohexol-380 and iohexol-350 groups (all, p > 
0.05).
Quantitative Efficacy Assessment: Contrast Enhancement
Table 3 showed the results of density measurements 
at the three anatomic regions. According to the final 
assessment, mean density of the ascending aorta was 
significantly higher in the iohexol-380 group than in the 
iohexol-350 group (p = 0.030). However, mean densities 
of the left main coronary artery and left ventricle were not 
different between the two groups.
Qualitative Efficacy Assessment: Image Quality Scoring
No differences in frequency according to image score 
category was found between the two readers and the final 
reports for all three anatomic evaluations (all, p > 0.05) 
(Table 4).
DISCUSSION
The principal findings of this study were first, 
iohexol-380, the new high concentration contrast 
medium on trial was as safe as the commercially available 
iohexol-350, with a similar incidence of mild adverse drug 
reactions and no incidence of severe adverse drug reactions; 
and second, the intravenous administration of iohexol-380 
provided higher attenuation of the ascending aorta but 
similar attenuation of the coronary arteries, as compared to 
iohexol-350 with an identical amount of absolute iodine.
A number of studies have shown the effectiveness 
of contrast media with a high iodine concentration for 
Table 4. Image Quality Scores for Visualization of Ascending Aorta, Left Main Coronary Artery and Left Ventricle
Region-of-Interest
Reader 1 Reader 2 Final Assessment
Iohexol-380
(n = 114)
Iohexol-350
(n = 110)
P
Iohexol-380
(n = 114)
Iohexol-350
(n = 110)
P
Iohexol-380
(n = 114)
Iohexol-350
(n = 110)
P
Ascending aorta 0.620 0.393 0.368
Score 1 0 (0.0) 0 (0.0)  0 (0.0) 1 (0.9)  0 (0.0) 1 (0.9)  
Score 2 4 (3.5) 2 (1.8) 2 (1.8) 0 (0.0) 2 (1.8) 0 (0.0)
Score 3 19 (16.7) 22 (20.0) 40 (35.1) 40 (36.4) 37 (32.5) 39 (35.5)
Score 4 91 (79.8) 86 (78.2) 72 (63.2) 69 (62.7) 75 (65.8) 70 (63.6)
Left main coronary artery 0.683 0.213 0.186
Score 1 0 (0.0) 1 (0.9)  0 (0.0) 2 (1.8)  0 (0.0) 2 (1.8)  
Score 2 11 (9.6) 8 (7.3) 11 (9.6) 5 (4.5) 10 (8.8) 4 (3.6)
Score 3 22 (19.3) 20 (18.2) 48 (42.1) 52 (47.3) 49 (43.0) 53 (48.2)
Score 4 81 (71.1) 81 (73.6) 55 (48.2) 51 (46.4) 55 (48.2) 51 (46.4)
Left ventricle 0.388 0.193 0.348
Score 1 0 (0.0) 0 (0.0)  0 (0.0) 1 (0.9)  0 (0.0) 1 (0.9)  
Score 2 9 (7.9) 4 (3.6) 10 (8.8) 3 (2.7) 8 (7.0) 3 (2.7)
Score 3 29 (25.4) 28 (25.5) 29 (25.4) 30 (27.3) 31 (27.2) 29 (26.4)
Score 4 76 (66.7) 78 (70.9) 75 (65.8) 76 (69.1) 75 (65.8) 77 (70.0)
Data in parentheses are percentages.
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vascular enhancement on CT angiography (5-7, 9, 13-15). 
In two studies by Cademartiri et al. (9), the injection rate 
and volume were identical in all groups of contrast media 
with differing iodine concentrations; therefore, higher 
iodine delivery rates and higher total iodine amounts were 
used in groups with high iodine concentrations. They 
concluded that significantly higher attenuation in coronary 
arteries as well as thoracic aorta was achieved with the 
highest iodine concentration (9, 13): comparison of 
iohexol-300, iodixanol-320, iohexol-350, iomeprol-350, and 
iomeprol-400 (13), and comparison between iopromide-370 
and iomeprol-400 (9). Partly in agreement with these 
previous studies (9, 13, 15), our results indicated higher 
attenuation in the ascending aorta but not in the 
coronary arteries with a contrast medium of high iodine 
concentration (iohexol-380), as compared with iohexol-350. 
This difference may have been due to the different 
injection protocols of the contrast media; identical iodine 
amounts of 420 mgI/kg with the same flow rate of 4 mL/
sec were used in both groups, resulting in differing iodine 
delivery rates and injection volume. Vascular enhancement, 
however, is determined by the iodine delivery rate (iodine 
flux) (16, 17). Previous studies have shown conflicting 
results for vascular attenuations using identical iodine 
delivery rates in several contrast media with differing 
iodine concentrations (10, 15, 18, 19). Rist et al. (15) used 
identical iodine delivery rates of 1 gI/s in both groups, and 
demonstrated that 63 mL of a contrast media with high 
iodine concentration (iomeprol-400) with a lower injection 
rate of 2.5 mL/s yielded equivalent coronary attention to 
that achieved after injection of 83 mL of iomeprol-300 at a 
rate of 3.3 mL/s. Another intra-individual comparison study 
of different contrast media concentrations (iopromide-300, 
iopromide-370, and iomeprol-400) in six pigs showed that 
the contrast medium with 300 mgI/mL provided improved 
contrast enhancement compared with a highly concentrated 
contrast medium in the thoracic aorta and pulmonary 
arteries, given identical iodine delivery rates and total 
iodine amount (18). It was assumed that lower viscosity and 
increased volume of iopromide-300 with a faster injection 
might enhance actual iodine delivery rates in the vessel, as 
compared to contrast media with higher concentrations (18, 
20). However, this might not be applicable for coronary CT 
angiography, as the injection rates used in clinical practice 
are typically high at 4 to 5 mL/s and injection rates cannot 
be increased further.
We recognized some limitations in our study. First, an 
intra-individual comparison could have eliminated patient 
bias from hemodynamic differences, but were not performed 
in our study owing to ethical concerns. Second, the contrast 
media injection protocol used in our study was somewhat 
complicated. Most previous studies used one of the two 
following methods. One method is to keep the injection rate 
and volume constant, with differing iodine administration 
rates (iodine delivery rate). This method is typically used 
to assess the effectiveness of vascular enhancement of a 
contrast medium with high iodine concentration. The other 
method is to use identical iodine administration rates with 
identical total iodine amount, but differing injection rates. 
This method can be used to prove the equivalent power 
of vascular enhancement of a contrast medium with low 
concentrations, as compared to contrast media with higher 
concentrations. In our study, we used identical injection 
rates to assess the improved vascular enhancement of a 
contrast medium with high iodine concentrations, resulting 
in different iodine administration rates between both 
groups. However, we used identical total iodine amounts to 
assess the safety of the new contrast medium, iohexol-380, 
resulting in different volumes between groups. Therefore, 
the efficacy of high concentration contrast medium on 
vascular enhancement may have been reduced; indeed, we 
failed to see improved enhancement in the coronary arteries 
using iohexol-380. Lastly, different injection durations 
in each individual owing to administration of different 
contrast volumes may also have affected the timing of peak 
enhancement despite bolus-tracking.
In conclusion, iohexol-380 provides improved 
enhancement of the ascending aorta and similar attenuation 
in the coronary arteries without any increase in adverse 
drug reactions, as compared with iohexol-350 using an 
identical amount of total iodine.
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